Featured Suppliers:

ORLANDO, Fla.--(BUSINESS WIRE)--In an investigational study, Merck's medicine COZAAR (losartan potassium tablets) 150 mg, administered once daily, significantly reduced

http://finance.yahoo.com/news/Higher-Dose-of-Mercks-COZAAR-bw-1721053602.html?x=0&.v=1

AHA: Tripling ARB Dose Improves HF Outcomes (CME/CE)

News | www.medpagetoday.com | Nov 17, 2009

ORLANDO -- High doses of the angiotensin receptor blocker (ARB) losartan (Cozaar) for heart failure patients who cannot tolerate an ACE inhibitor may reduce mortality and heart failure hospitalization

http://www.medpagetoday.com/MeetingCoverage/AHA/17051

Merck News Item

News | www.merck.com | Nov 17, 2009

ORLANDO, FL., Nov. 17, 2009 - In an investigational study, Merck's medicine COZAAR (losartan potassium tablets) 150 mg, administered once daily, significantly reduced the risk of all-cause death or hospitalization due to heart failure compared to a lower 50 mg once daily dose of COZAAR.

http://www.merck.com/newsroom/news-release-archive/product/2009_1117.html?src=rss

High Blood Pressure Medicines Show Promise For Treating Heart Disease

Press Release | www.prnewswire.com | Oct 19, 2009

However, the drugs have risks of their own. Risks associated with ACE inhibitors include a persistent cough, sudden fainting, too much potassium in the blood, and dangerously low blood pressure (hypotension).

http://www.prnewswire.com/news-releases/high-blood-pressure-medicines-show-promise-for-treating-heart-disease-64827362.html

FDA Approves New Use for Boehringer Ingelheim Corporation's Micardis(R) in Cardiovascular Risk

News | www.biospace.com | Oct 19, 2009

(1) MICARDIS is the most studied ARB in this high-risk patient population and has been commercially available to treat hypertension (high blood pressure) since its approval in 1998.

http://www.biospace.com/news_story.aspx?StoryID=159552&full=1

Sponsored Links

The Cardiovascular Forum

Interactive Cases, Forums, Images. Free Membership !

www.cardiovascularcs.org/

Cardiovascular Technician

Search Healthcare Schools for Cardiovascular Technology Training

GuideToHealthcareSchools.com/Cardio

Waiting for New Novartis HBP Drug

Blog | seekingalpha.com | Sep 28, 2009

Zacks.com submits: Novartis (NVS) is expected to launch its

http://seekingalpha.com/article/163789-waiting-for-new-novartis-hbp-drug?source=feed

FDA Clears Novartis’ Combo Pill for Blood Pressure

News | www.genengnews.com | Sep 18, 2009

FDA approved Novartis’ blood pressure treatment Valturna®. Clearance in the U.S. represents the first for the drug, which is a single pill combination of Novartis’

http://www.genengnews.com/news/bnitem.aspx?name=63096432

Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure

Press Release | news.prnewswire.com | Sep 17, 2009

"This unique combination brings together the powerful blood pressure lowering effects of valsartan and aliskiren," said Joe Jimenez, CEO of the Novartis Pharmaceuticals Division.

http://news.prnewswire.com/ViewContent.aspx?ACCT=109&STORY=/www/story/09-17-2009/0005096263&EDATE=

FDA Approves Novartis' Valturna - Pharmaceutical Business Review

News | www.pharmaceutical-business-review.com | Sep 17, 2009

The FDA has Novartis' approved Valturna (aliskiren and valsartan) tablets, a medicine to target two key points within the renin system, also known as the renin angiotensin aldosterone system (RAAS).

http://www.pharmaceutical-business-review.com/news/fda_approves_novartis_valturna_090917

Irish Medical Times | Clinical TImes | Surgery risk from ACE inhibitors

News | www.imt.ie | Sep 16, 2009

In the study, Australian researchers tracked the eye health of over 3,500 people for between five and 10 years. At the start of the study in 1992-4, all participants were at least 49 years old.

http://www.imt.ie/clinical/ear-nose-and-throat/surgery-risk-from-ace-inhibito.html